Athens, Greece (UroToday.com) Dr. Boris Hadaschik presented on the disease entity of non-metastatic castrate-resistant prostate cancer (nmCRPC). According to Dr. Hadaschik, the short answer to whether this disease is: YES, as there are guideline-approved drugs for this unique disease entity. This disease entity is unique and it is the bridge to metastatic castrate-resistant prostate cancer (mCRPC), […]
Alicia Morgans: Hi. This is Alicia Morgans, medical oncologist at Northwestern University. I am thrilled to have here with me today Dr. Bishoy Faltas, who is a Medical Oncologist joining us from Weill Cornell where he is the Director of Bladder Cancer Research of the Englander Institute for Precision Medicine, and also an Assistant Professor […]
Athens, Greece (UroToday.com) Dr. Tilki presented on the impact of positive surgical margins, biochemical recurrence and PSA persistence on the oncological outcomes after undergoing radical prostatectomy. Margin status is positive if tumor cells are in contact with the ink on the specimen surface. Surgical margins are an independent risk factor for biochemical recurrence, but not all […]
Athens, Greece (UroToday.com) Dr. Robin Roberts gave an overview of the implementation of early detection of prostate cancer in the Bahamas. In the Bahamas, 70-80% of patients are present with advanced prostate cancer, which is a staggeringly high number. Unfortunately, all the significant advances in the treatment of advanced prostate cancer in the last 15 […]
Athens, Greece (UroToday.com) Dr. Carlsson gave an encompassing presentation on prostate cancer screening from the perspective of an epidemiologist. She began discussing the factors that affect prostate cancer mortality. Three distinct factors can reduce the mortality of prostate cancer. These include: Removal of carcinogens Better treatments Screening The World Health Organization (WHO) defines screening as […]
Rosland Eeles: Thanks very much, Robin. Thanks for the organizers for this fantastic meeting and a plea because I think we really need your help, as you’ll see as I go through this talk. So, I was given the task of looking at which men need, well, really, testing, first of all. I think the […]
We evaluated the effect of neoadjuvant chemotherapy in patients undergoing radical cystectomy for urothelial bladder cancer. We retrospectively examined 140 consecutive patients with muscle-invasive bladder cancer (clinical stage T2 to T4 and N0) who underwent radical cystectomy with or without neoadjuvant chemotherapy at four academic institutions between January 2006 and December 2016. Patients were categorized […]
The use of liquid biopsy on the blood from solid malignancies provides a convenient way of detecting actionable mutations, monitoring treatment response, detecting early recurrence and prognosticating outcomes. The aim of this review is to discuss the current status and future direction of serum biomarkers in the clinical management of urinary bladder cancer. This review […]
Durvalumab has shown meaningful clinical activity in patients with metastatic urothelial carcinoma (mUC) in Study 1108 (NCT01693562). An important focus in treatment is health-related quality of life (HRQOL). Here, patient-reported outcomes (PROs) from Study 1108 and their relationship with inflammatory biomarkers are explored. Disease-related symptoms, functioning, and HRQOL were assessed with the Functional Assessment of […]
Hydronephrosis is a common finding in patients with bladder cancer. The aim of the study was to appraise the prognostic value of preoperative hydronephrosis in bladder cancer patients undergoing radical cystectomy. We conducted a literature search using PubMed and Embase databases in Aug 2018. Summary hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated […]
